Low Output Heart Failure

  • Jeremy Robbins
  • Marwa A. Sabe
Part of the Clinical Cases in Cardiology book series (CCC)


Low-output heart failure represents a high-acuity, heterogeneous physiologic state marked by end-organ hypoperfusion and substantial morbidity and mortality. The clinical symptoms and exam findings vary widely, and it may manifest subtly with non-specific features of fatigue or sinus tachycardia, or present dramatically with altered sensorium, marked hypotension, and multi-organ failure. The diverse presentation of low-output heart failure highlights the importance of its prompt recognition and subsequent risk stratification. Treatment goals are focused on initial stabilization of systemic blood pressure and improved tissue and end-organ perfusion, and may be achieved through a combination of veno- and vasodilators, inotropic agents, and in severe cases, mechanical circulatory support. The following case presentation illustrates the complex findings seen in low-output heart failure, and offers a systematic approach to its evaluation and management.


Cardiomyopathy Dilated Left sided heart failure 


  1. 1.
    Nohria A, Tsang SW, Fang JC, et al. Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure. J Am Coll Cardiol. 2003;41(10):1797–804.CrossRefPubMedGoogle Scholar
  2. 2.
    Cleland JG, Dargie HJ, Ford I. Mortality in heart failure: clinical variables of prognostic value. Br Heart J. 1987;58(6):572–82.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Stevenson LW, Perloff JK. The limited reliability of physical signs for estimating hemodynamics in chronic heart failure. JAMA. 1989;261(6):884–8.CrossRefPubMedGoogle Scholar
  4. 4.
    Gleason WL, Braunwald E. Studies on Starling’s law of the heart. VI. Relationships between left ventricular end diastolic volume and stroke volume in man with observations on the mechanism of pulsus alternans. Circulation. 1962;25:841–8.CrossRefPubMedGoogle Scholar
  5. 5.
    Klein L, O’Connor CM, Leimberger JD, et al. Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the outcomes of a prospective trial of intravenous milrinone for exacerbations of chronic heart failure (OPTIME-CHF) study. Circulation. 2005;111(19):2454–60.CrossRefPubMedGoogle Scholar
  6. 6.
    Binanay C, Califf RM, Hasselblad V, et al. Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial. JAMA. 2005;294(13):1625–33.CrossRefPubMedGoogle Scholar
  7. 7.
    Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128(16):1810–52.CrossRefPubMedGoogle Scholar
  8. 8.
    Coletta AP, Cleland JG, Freemantle N, Clark AL. Clinical trials update from the European Society of Cardiology Heart Failure meeting: SHAPE, BRING-UP 2 VAS, COLA II, FOSIDIAL, BETACAR, CASINO and meta-analysis of cardiac resynchronisation therapy. Eur J Heart Fail. 2004;6(5):673–6.CrossRefPubMedGoogle Scholar
  9. 9.
    Felker GM, Benza RL, Chandler AB, et al. Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. J Am Coll Cardiol. 2003;41(6):997–1003.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Beth Israel Deaconess Medical Center, Harvard Medical SchoolBostonUSA

Personalised recommendations